Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
Yükleniyor...
Dosyalar
Tarih
2013
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Korean Neuropsychiatric Assoc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
Açıklama
Anahtar Kelimeler
Sigma receptor, Fluvoxamine, Akathisia, Dyskinesia, Induced Movement-Disorders, Neuropsychiatric Disorders, Receptor Ligands, Tomography, Chaperone, Dopamine, Stress, Brain, Drugs
Kaynak
Psychiatry Investigation
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
10
Sayı
4
